Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Buy" by Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been given a consensus rating of "Buy" by the nine research firms that are presently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $36.56.

A number of analysts have recently issued reports on XNCR shares. JPMorgan Chase & Co. lifted their price objective on shares of Xencor from $27.00 to $28.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. BMO Capital Markets reiterated an "outperform" rating and issued a $34.00 price target (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. Royal Bank of Canada lifted their target price on Xencor from $31.00 to $34.00 and gave the company an "outperform" rating in a research report on Thursday, September 26th. Finally, Wells Fargo & Company assumed coverage on Xencor in a research report on Thursday, December 12th. They set an "overweight" rating and a $37.00 price target for the company.

Insider Transactions at Xencor

In other Xencor news, Director Alan Bruce Montgomery sold 1,421 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total transaction of $38,409.63. Following the transaction, the director now owns 9,140 shares in the company, valued at $247,054.20. This trade represents a 13.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of the business's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now directly owns 200,104 shares of the company's stock, valued at approximately $4,698,441.92. The trade was a 25.55 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 136,050 shares of company stock worth $3,277,609. 5.23% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Quarry LP acquired a new stake in Xencor during the second quarter worth approximately $36,000. GAMMA Investing LLC grew its holdings in shares of Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 508 shares in the last quarter. KBC Group NV grew its holdings in shares of Xencor by 63.5% during the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 1,213 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Xencor in the third quarter worth $205,000. Finally, XTX Topco Ltd acquired a new position in Xencor in the second quarter valued at about $196,000.

Xencor Stock Down 2.1 %

XNCR traded down $0.51 during trading on Thursday, hitting $23.43. The company had a trading volume of 438,480 shares, compared to its average volume of 496,996. The company has a market capitalization of $1.64 billion, a PE ratio of -7.32 and a beta of 0.72. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor has a one year low of $15.31 and a one year high of $27.24. The firm's 50-day moving average price is $24.14 and its 200 day moving average price is $20.96.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating analysts' consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. During the same period in the previous year, the company posted ($0.40) earnings per share. The company's quarterly revenue was down 81.9% compared to the same quarter last year. As a group, equities analysts expect that Xencor will post -3.71 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.